Journey Medical

DERM

Market cap $187M

Overview Fund Activity

7.12 USD

+0.01

0.14%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

7.12

0.00

0%

1 day

0.14%

5 days

1.57%

1 month

2.45%

3 months

5.64%

6 months

34.09%

Year to date

78%

1 year

31.12%

5 years

-25.05%

10 years

-25.05%

About: Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Employees: 41

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

257% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 7

55% more capital invested

Capital invested by funds: $30M [Q1] → $46.6M (+$16.6M) [Q2]

47% more funds holding

Funds holding: 38 [Q1] → 56 (+18) [Q2]

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

7.82% more ownership

Funds ownership: 29.71% [Q1] → 37.54% (+7.82%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

69% upside

Avg. target

$12.67

78% upside

High target

$13

83% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Brandon Folkes	$13	Buy Initiated	25 Aug 2025
Lake Street Thomas Flaten	$13	Buy Maintained	13 Aug 2025
B. Riley Securities Kalpit Patel	$12	Buy Maintained	30 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about DERM published over the past 30 days

Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon

EMROSI's strong launch is driving Journey Medical's growth, with rapid prescription uptake, expanding prescriber base, and improved payer coverage fueling margin expansion. I see EMROSI as the primary value driver, positioning DERM for sustainable EBITDA profitability by year-end and strong long-term revenue and EPS growth potential. Key risks include Accutane's generic erosion, uncertainty in EMROSI's net revenue per script, and limited cash reserves that may require future capital raises.

Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon

Zacks Investment Research

New Strong Sell Stocks for September 4th

DERM, HOPE and NXRT have been added to the Zacks Rank #5 (Strong Sell) List on September 4, 2025.

New Strong Sell Stocks for September 4th

Journey Medical Corporation to Participate in September 2025 Investor Conferences

SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences.

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Journey Medical Corporation to Present at the Emerging Growth Conference

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts.

Journey Medical Corporation to Present at the Emerging Growth Conference

CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Wednesday.

CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript

Journey Medical Corporation (NASDAQ:DERM ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Claude Maraoui - Founder, President, CEO & Director Jaclyn Jaffe - Senior Director of Corporate Operations Joseph M. Benesch - CFO & Corporate Controller Ramsey Alloush - COO, General Counsel & Company Secretary Conference Call Participants Mayank Mamtani - B.

Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.17 per share a year ago.

Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Zacks Investment Research

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Square on Monday, August 11, 2025 at 4:00 p.m. ET. Journey Medical is celebrating its 4-year anniversary as a publicly traded company on the Nasdaq Stock Market and the commercial launch of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for the treatment of rosacea.

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

See News Rankings

Charts implemented using Lightweight Charts™